Moderna presented 5-year melanoma data at ASCO 2026
The combination of intismeran autogene and KEYTRUDA showed sustained improvement in relapse-free survival and distant metastasis-free survival compared with KEYTRUDA alone.
See the latest news and media coverage for Moderna. We track all announcements, press releases, and industry mentions in real time, all in one place.
mRNA therapeutics and vaccine developer
modernatx.comLast updated
In short: Moderna expanded its executive leadership and secured EU approval for a combo flu-COVID shot while advancing its oncology and influenza pipeline.
The combination of intismeran autogene and KEYTRUDA showed sustained improvement in relapse-free survival and distant metastasis-free survival compared with KEYTRUDA alone.
The New England Journal of Medicine publishes safety and efficacy data from study P304 in adults aged 50+.
Vertex terminates Phase 1/2 study of VX-522 due to tolerability issues. No broader portfolio impact; learnings inform future efforts.
Executive team discusses financial performance and late-stage pipeline milestones in IR Insights video. Plans include 10% revenue growth and expense reductions.
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than...
Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Making Investors Richer. Moderna extended its winning streak to a fifth consecutive day on Wednesday,...
U.S. vaccine maker Moderna (MRNA) is exploring investments in manufacturing facilities in Germany and is particularly interested in acquiring sites that rival BioNTech (BNTX) plans to shut.
Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks With Standout Gains. Moderna extended its winning...
Track Moderna and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.